Metformina Alter (Metformin Hydrochloride)

Metformin reduces hepatic glucose production, enhances peripheral insulin sensitivity, and modestly decreases intestinal glucose absorption. By acting on the liver, muscle, and gut, it lowers both fasting and post‑prandial blood‑glucose levels without stimulating insulin secretion.

The specific dose of Metformina Alter is determined by the prescribing clinician based on the patient’s clinical condition, renal function, and response to therapy. Dosage adjustments are made individually and should follow the prescriber’s instructions.

Safety of metformin during pregnancy or lactation depends on clinical judgment. While some guidelines allow its use in certain pregnant patients with gestational diabetes, the decision should be made by a qualified healthcare professional after weighing potential benefits and risks.

To request Metformina Alter, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any necessary import documentation.

Metformina Alter (metformin) belongs to the biguanide class and is often first‑line therapy for type 2 diabetes because of its efficacy, low risk of hypoglycemia, and favorable impact on weight. Compared with sulfonylureas or insulin, it does not stimulate insulin release and has a distinct safety profile, making it a preferred option for many patients.

Metformina Alter should be stored at ambient temperature, below 25 °C, in its original packaging to protect it from moisture and light. Keep the tablets out of reach of children and do not use them after the expiry date printed on the label.

Metformina Alter is taken orally, usually with meals to reduce gastrointestinal discomfort. The tablets are swallowed whole with a glass of water. Patients should follow the dosing schedule prescribed by their healthcare provider.

The most serious adverse events include lactic acidosis, a rare but potentially fatal condition, and severe hypoglycemia when combined with insulin or sulfonylureas. Patients should be educated to recognize symptoms such as rapid breathing, muscle pain, or unusual fatigue and seek immediate medical attention if they occur.

Metformina Alter is contraindicated in patients with severe renal impairment (eGFR < 30 mL/min/1.73 m²), known hypersensitivity to metformin, acute or chronic metabolic acidosis, including diabetic ketoacidosis, and in those with conditions predisposing to hypoxia such as severe heart or lung disease.